Thrombosis formation on atherosclerotic lesions and plaque rupture

Journal of Internal Medicine

Volumn 276, Issue 6, 2014, Pages 618-632

  Badimon, L ^a,b   Vilahur, G ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherosclerosis; Atherosclerotic plaque; Coagulation; Lipids; Platelets; Thrombosis

Indexed keywords

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CLASSIFICATION; FIBRINOLYSIS; HUMAN; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; RUPTURE; THROMBOSIS; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; NECROSIS; PLAQUE, ATHEROSCLEROTIC; RUPTURE, SPONTANEOUS; THROMBOSIS;

EID: 84911364795     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12296     Document Type: Review

References (109)

1. Vilahur G, Badimon J, Bugiardini R, Badimon L. Perspectives: the burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide. Eur Heart J 2014; 16: A7-11.
2. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
5. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045-51.
6. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2012; 105(Suppl 1): S34-42.
7. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-91.
8. McLeod O, Silveira A, Fredrikson GN et al. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis. Atherosclerosis 2014; 232: 242-8.
9. Badimon L. Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis. Cardiovasc Res 2012; 96: 172-5; discussion 6-80.
10. Libby P, Nahrendorf M, Swirski FK. Monocyte heterogeneity in cardiovascular disease. Semin Immunopathol 2013; 35: 553-62.
11. Koga J, Aikawa M. Crosstalk between macrophages and smooth muscle cells in atherosclerotic vascular diseases. Vascul Pharmacol 2013; 57: 24-8.
12. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010; 10: 36-46.
13. Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-61.
14. Study Group on the Classification of Atherosclerotic Lesions. World Health Organ Tech Rep Ser 1958; 57: 1-20.
15. Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-74.
16. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
17. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
18. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ 2013; 22: 399-411.
19. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013; 34: 719-28.
20. Tomey MI, Narula J, Kovacic JC. Year in review: advances in understanding of plaque composition and treatment options. J Am Coll Cardiol 2014; 63: 1604-16.
21. Brugaletta S, Cola C, Martin-Yuste V et al. Qualitative and quantitative accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries. Int J Cardiovasc Imaging 2014; 30: 469-76.
22. Joshi F, Rosenbaum D, Bordes S, Rudd JH. Vascular imaging with positron emission tomography. J Intern Med 2011; 270: 99-109.
23. von Birgelen C, Klinkhart W, Mintz GS et al. Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel: an intravascular ultrasound study in vivo. J Am Coll Cardiol 2001; 37: 1864-70.
24. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000; 101: 598-603.
25. Kojima S, Nonogi H, Miyao Y et al. Is preinfarction angina related to the presence or absence of coronary plaque rupture? Heart 2000; 83: 64-8.
26. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17: 1337-45.
27. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992; 71: 850-8.
28. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-4.
29. Padro T, Pena E, Garcia-Arguinzonis M, Llorente-Cortes V, Badimon L. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc Res 2008; 77: 211-20.
30. Garcia-Arguinzonis M, Padro T, Lugano R, Llorente-Cortes V, Badimon L. Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2010; 30: 1212-9.
31. Bauriedel G, Hutter R, Welsch U, Bach R, Sievert H, Luderitz B. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc Res 1999; 41: 480-8.
32. Stoneman VE, Bennett MR. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci (Lond) 2004; 107: 343-54.
33. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003; 23: 1553-8.
34. Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18: 5197-214.
35. Tedgui A, Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001; 86: 420-6.
36. Fernandez-Ortiz A, Badimon JJ, Falk E et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-9.
37. Pena E, Arderiu G, Badimon L. Tissue factor induces human coronary artery smooth muscle cell motility through Wnt-signalling. J Thromb Haemost 2013; 11: 1880-91.
38. Pena E, Arderiu G, Badimon L. Subcellular localization of tissue factor and human coronary artery smooth muscle cell migration. J Thromb Haemost 2012; 10: 2373-82.
39. Shah PK, Falk E, Badimon JJ et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
40. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
41. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol 1995; 147: 251-66.
42. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998; 135: 10-4.
43. Koole D, Heyligers J, Moll FL, Pasterkamp G. Intraplaque neovascularization and hemorrhage: markers for cardiovascular risk stratification and therapeutic monitoring. J Cardiovasc Med (Hagerstown) 2012; 13: 635-9.
44. Hellings WE, Peeters W, Moll FL et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010; 121: 1941-50.
45. Barger AC, Beeuwkes R 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-7.
46. McCarthy MJ, Loftus IM, Thompson MM et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999; 30: 261-8.
47. Polverini PJ, Cotran PS, Gimbrone MA Jr, Unanue ER. Activated macrophages induce vascular proliferation. Nature 1977; 269: 804-6.
48. Moreno PR, Purushothaman M, Purushothaman KR. Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. Ann N Y Acad Sci 2012; 1254: 7-17.
49. Kolodgie FD, Gold HK, Burke AP et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25.
50. Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M, Badimon L. [Neovascularization in human coronary arteries with lesions of different severity]. Rev Esp Cardiol 2003; 56: 978-86.
51. Slevin M, Krupinski J, Badimon L. Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention. J Angiogenes Res 2009; 1: 4.
52. Slevin M, Turu MM, Rovira N et al. Identification of a 'snapshot' of co-expressed angiogenic markers in laser-dissected vessels from unstable carotid plaques with targeted arrays. J Vasc Res 2010; 47: 323-35.
53. Arderiu G, Pena E, Aledo R, Espinosa S, Badimon L. Ets-1 transcription is required in tissue factor driven microvessel formation and stabilization. Angiogenesis 2012; 15: 657-69.
54. Arderiu G, Pena E, Aledo R, Badimon L. Tissue factor-Akt signaling triggers microvessel formation. J Thromb Haemost 2012; 10: 1895-905.
55. Arderiu G, Pena E, Aledo R, Juan-Babot O, Badimon L. Tissue factor regulates microvessel formation and stabilization by induction of chemokine (C-C motif) ligand 2 expression. Arterioscler Thromb Vasc Biol 2011; 31: 2607-15.
56. Sangiorgi G, Rumberger JA, Severson A et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 1998; 31: 126-33.
57. Ehara S, Kobayashi Y, Yoshiyama M et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 2004; 110: 3424-9.
58. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol 2001; 21: 1618-22.
59. Xu Y, Mintz GS, Tam A et al. Prevalence, distribution, predictors, and outcomes of patients with calcified nodules in native coronary arteries: a 3-vessel intravascular ultrasound analysis from Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT). Circulation 2012; 126: 537-45.
60. Maldonado N, Kelly-Arnold A, Vengrenyuk Y et al. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. Am J Physiol Heart Circ Physiol 2012; 303: H619-28.
61. Yuan C, Mitsumori LM, Ferguson MS et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001; 104: 2051-6.
62. Seneviratne A, Hulsmans M, Holvoet P, Monaco C. Biomechanical factors and macrophages in plaque stability. Cardiovasc Res 2013; 99: 284-93.
63. Giannoglou GD, Antoniadis AP, Koskinas KC, Chatzizisis YS. Flow and atherosclerosis in coronary bifurcations. EuroIntervention 2010; 6(Suppl J): J16-23.
64. Lee RT, Kamm RD. Vascular mechanics for the cardiologist. J Am Coll Cardiol 1994; 23: 1289-95.
65. Burke AP, Farb A, Malcom GT, Liang Y, Smialek JE, Virmani R. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999; 281: 921-6.
66. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol 2013; 61: 1-11.
67. Thrall G, Lane D, Carroll D, Lip GY. A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: implications for the pathogenesis of acute coronary syndromes. Thromb Res 2007; 120: 819-47.
68. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 2006; 86: 279-367.
69. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol 2012; 9: 439-53.
70. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20: 333-8.
71. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339-47.
72. Badimon L, Vilahur G. Platelets, arterial thrombosis and cerebral ischemia. Cerebrovasc Dis 2007; 24(Suppl 1): 30-9.
73. Penz S, Reininger AJ, Brandl R et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005; 19: 898-909.
74. Owens AP 3rd, Mackman N. Tissue factor and thrombosis: the clot starts here. Thromb Haemost 2010; 104: 432-9.
75. Grad E, Danenberg HD. C-reactive protein and atherothrombosis: cause or effect? Blood Rev 2013; 27: 23-9.
76. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-46.
77. Molins B, Pena E, de la Torre R, Badimon L. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc Res 2011; 92: 328-37.
78. de la Torre R, Pena E, Vilahur G, Slevin M, Badimon L. Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition. J Thromb Haemost 2013; 11: 2048-58.
79. Habersberger J, Strang F, Scheichl A et al. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res 2012; 96: 64-72.
80. Cimmino G, Conte S, Morello A, D'Elia S, Marchese V, Golino P. The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations. Expert Rev Cardiovasc Ther 2012; 10: 1533-43.
81. http://www.acc.orgACoCaAHAAAEpgmopwafoAfU.
82. Andrews RK, Gardiner EE, Shen Y, Berndt MC. Platelet interactions in thrombosis. IUBMB Life 2004; 56: 13-8.
83. Peterson ED, Pollack CV Jr, Roe MT et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 2003; 42: 45-53.
84. Hemker HC, van Rijn JL, Rosing J, van Dieijen G, Bevers EM, Zwaal RF. Platelet membrane involvement in blood coagulation. Blood Cells 1983; 9: 303-17.
85. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-50.
86. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-8.
87. Badimon L, Vilahur G, Padro T. Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol 2009; 62: 1161-78.
88. Celi A, Merrill-Skoloff G, Gross P et al. Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. J Thromb Haemost 2003; 1: 60-8.
89. Mailhac A, Badimon JJ, Fallon JT et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 1994; 90: 988-96.
90. Meyer BJ, Badimon JJ, Mailhac A et al. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation 1994; 90: 2432-8.
91. Toschi V, Gallo R, Lettino M et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
92. Badimon JJ, Lettino M, Toschi V et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
93. Badimon JJ, Ortiz AF, Meyer B et al. Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening. Atherosclerosis 1998; 140: 307-14.
94. Egorina EM, Sovershaev MA, Bjorkoy G et al. Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability. Arterioscler Thromb Vasc Biol 2005; 25: 1493-8.
95. Camino-Lopez S, Llorente-Cortes V, Sendra J, Badimon L. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. Cardiovasc Res 2007; 73: 208-16.
96. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-9.
97. Day SM, Reeve JL, Pedersen B et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-8.
98. Ramaiola I, Padro T, Juan-Babot O et al. Relationship between time of ischemia and thrombus composition in STEMI. ESC congress 2012.Eur Heart J 2012; 33(Suppl 1): 473 (P2730).
99. Silvain J, Collet JP, Nagaswami C et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57: 1359-67.
100. Abbate R, Cioni G, Ricci I, Miranda M, Gori AM. Thrombosis and acute coronary syndrome. Thromb Res 2012; 129: 235-40.
101. Foley JH, Kim PY, Mutch NJ, Gils A. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. J Thromb Haemost 2013; 11(Suppl 1): 306-15.
102. Woodward M, Lowe GD, Rumley A et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97: 785-97.
103. Osende JI, Badimon JJ, Fuster V et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307-12.
104. Amabile N, Rautou PE, Tedgui A, Boulanger CM. Microparticles: key protagonists in cardiovascular disorders. Semin Thromb Hemost 2010; 36: 907-16.
105. Suades R, Padro T, Alonso R, Mata P, Badimon L. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells indicating protection against cell activation. Thromb Haemost 2013; 110: 366-77.
106. Suades R, Padro T, Vilahur G, Badimon L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost 2012; 108: 1208-19.
107. Celi A, Lorenzet R, Furie BC, Furie B. Microparticles and a P-selectin-mediated pathway of blood coagulation. Dis Markers 2004; 20: 347-52.
108. Beohar N, Flaherty JD, Davidson CJ et al. Antirestenotic effects of a locally delivered caspase inhibitor in a balloon injury model. Circulation 2004; 109: 108-13.
109. Zhang N, Xie X, Chen H, Yu H, Wang JA. Stem cell-based therapies for atherosclerosis: perspectives and ongoing controversies. Stem Cells Dev 2014; 23: 1731-40.